Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 2
2004 3
2005 2
2006 6
2007 4
2008 5
2009 4
2010 6
2011 8
2012 6
2013 8
2014 10
2015 6
2016 4
2017 9
2018 15
2019 16
2020 16
2021 18
2022 12
2023 12
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

150 results

Results by year

Filters applied: . Clear all
Page 1
NCCN Guidelines® Insights: B-Cell Lymphomas, Version 6.2023.
Zelenetz AD, Gordon LI, Abramson JS, Advani RH, Andreadis B, Bartlett NL, Budde LE, Caimi PF, Chang JE, Christian B, DeVos S, Dholaria B, Fayad LE, Habermann TM, Hamid MS, Hernandez-Ilizaliturri F, Hu B, Kaminski MS, Karimi Y, Kelsey CR, King R, Krivacic S, LaCasce AS, Lim M, Messmer M, Narkhede M, Rabinovitch R, Ramakrishnan P, Reid E, Roberts KB, Saeed H, Smith SD, Svoboda J, Swinnen LJ, Tuscano J, Vose JM, Dwyer MA, Sundar H. Zelenetz AD, et al. Among authors: smith sd. J Natl Compr Canc Netw. 2023 Nov;21(11):1118-1131. doi: 10.6004/jnccn.2023.0057. J Natl Compr Canc Netw. 2023. PMID: 37935098
Burkitt Lymphoma International Prognostic Index.
Olszewski AJ, Jakobsen LH, Collins GP, Cwynarski K, Bachanova V, Blum KA, Boughan KM, Bower M, Dalla Pria A, Danilov A, David KA, Diefenbach C, Ellin F, Epperla N, Farooq U, Feldman TA, Gerrie AS, Jagadeesh D, Kamdar M, Karmali R, Kassam S, Kenkre VP, Khan N, Kim SH, Klein AK, Lossos IS, Lunning MA, Martin P, Martinez-Calle N, Montoto S, Naik S, Palmisiano N, Peace D, Phillips EH, Phillips TJ, Portell CA, Reddy N, Santarsieri A, Sarraf Yazdy M, Smeland KB, Smith SE, Smith SD, Sundaram S, Zayac AS, Zhang XY, Zhu C, Cheah CY, El-Galaly TC, Evens AM. Olszewski AJ, et al. Among authors: smith sd. J Clin Oncol. 2021 Apr 1;39(10):1129-1138. doi: 10.1200/JCO.20.03288. Epub 2021 Jan 27. J Clin Oncol. 2021. PMID: 33502927 Free PMC article.
NCCN Guidelines® Insights: B-Cell Lymphomas, Version 5.2021.
Zelenetz AD, Gordon LI, Chang JE, Christian B, Abramson JS, Advani RH, Bartlett NL, Budde LE, Caimi PF, De Vos S, Dholaria B, Fakhri B, Fayad LE, Glenn MJ, Habermann TM, Hernandez-Ilizaliturri F, Hsi E, Hu B, Kaminski MS, Kelsey CR, Khan N, Krivacic S, LaCasce AS, Lim M, Narkhede M, Rabinovitch R, Ramakrishnan P, Reid E, Roberts KB, Saeed H, Smith SD, Svoboda J, Swinnen LJ, Tuscano J, Vose JM, Dwyer MA, Sundar H. Zelenetz AD, et al. Among authors: smith sd. J Natl Compr Canc Netw. 2021 Nov;19(11):1218-1230. doi: 10.6004/jnccn.2021.0054. J Natl Compr Canc Netw. 2021. PMID: 34781267
Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial.
Wang M, Rule S, Zinzani PL, Goy A, Casasnovas O, Smith SD, Damaj G, Doorduijn J, Lamy T, Morschhauser F, Panizo C, Shah B, Davies A, Eek R, Dupuis J, Jacobsen E, Kater AP, Le Gouill S, Oberic L, Robak T, Covey T, Dua R, Hamdy A, Huang X, Izumi R, Patel P, Rothbaum W, Slatter JG, Jurczak W. Wang M, et al. Among authors: smith sd. Lancet. 2018 Feb 17;391(10121):659-667. doi: 10.1016/S0140-6736(17)33108-2. Epub 2017 Dec 11. Lancet. 2018. PMID: 29241979 Free PMC article. Clinical Trial.
Concurrent pembrolizumab with AVD for untreated classic Hodgkin lymphoma.
Lynch RC, Ujjani CS, Poh C, Warren EH, Smith SD, Shadman M, Till B, Raghunathan VM, Alig S, Alizadeh AA, Gulhane A, Chen DL, Tseng Y, Coye H, Shelby M, Ottemiller S, Keo S, Verni K, Du H, Vandermeer J, Gaston A, Rasmussen H, Martin P, Marzbani E, Voutsinas J, Gopal AK. Lynch RC, et al. Among authors: smith sd. Blood. 2023 May 25;141(21):2576-2586. doi: 10.1182/blood.2022019254. Blood. 2023. PMID: 36913694 Free PMC article. Clinical Trial.
Gemcitabine: End of a Chemotherapy's Era?
Smith SD. Smith SD. Acta Haematol. 2019;141(2):91-92. doi: 10.1159/000496098. Epub 2019 Jan 10. Acta Haematol. 2019. PMID: 30630165 Free article. No abstract available.
Final results and overall survival data from a phase II study of acalabrutinib monotherapy in patients with relapsed/refractory mantle cell lymphoma, including those with poor prognostic factors.
Le Gouill S, Długosz-Danecka M, Rule S, Zinzani PL, Goy A, Smith SD, Doorduijn JK, Panizo C, Shah BD, Davies AJ, Eek R, Jacobsen E, Kater AP, Robak T, Jain P, Calvo R, Tao L, Wang M. Le Gouill S, et al. Among authors: smith sd. Haematologica. 2024 Jan 1;109(1):343-350. doi: 10.3324/haematol.2022.282469. Haematologica. 2024. PMID: 37470152 Free PMC article. No abstract available.
Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma: a phase 1b/2 trial.
Budde LE, Olszewski AJ, Assouline S, Lossos IS, Diefenbach C, Kamdar M, Ghosh N, Modi D, Sabry W, Naik S, Mehta A, Nakhoda SK, Smith SD, Dorritie K, Jia T, Pham S, Huw LY, Jing J, Wu H, Ead WS, To I, Batlevi CL, Wei MC, Chavez JC. Budde LE, et al. Among authors: smith sd. Nat Med. 2024 Jan;30(1):229-239. doi: 10.1038/s41591-023-02726-5. Epub 2023 Dec 10. Nat Med. 2024. PMID: 38072960 Free PMC article. Clinical Trial.
150 results